Edge­wise boosts aware­ness of rare Beck­er mus­cu­lar dy­s­tro­phy as it pur­sues po­ten­tial first ther­a­py

As Edge­wise Ther­a­peu­tics works to­wards its first FDA drug ap­proval, the small bio­phar­ma is al­ready launch­ing re­sources for one of the rare dis­ease com­mu­ni­ties it aims to help.

The dis­or­der is Beck­er mus­cu­lar dy­s­tro­phy, which af­fects about 5,000 peo­ple in the US and of­ten sits in the shad­ow of the bet­ter-known con­di­tion Duchenne mus­cu­lar dy­s­tro­phy. The con­di­tions are sim­i­lar­ly the re­sult of pro­tein mu­ta­tions that cause pro­gres­sive mus­cle dam­age, but Beck­er symp­toms typ­i­cal­ly ap­pear lat­er in life. Duchenne’s pa­tients of­ten start show­ing symp­toms by 1 to 2 years old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER